高血压伴高尿酸血症患者服用左氨氯地平的疗效  

Effect of levoamlodipine on hypertensive patients with hyperuricemia

作　　者：倪伟[1] 陈桂秀[1] 王浩宇[1] 刘涛[1] NI Wei;CHEN Guixiu;WANG Haoyu;LIU Tao(Deparment of Cardiology,Nanchong Central Hospital,the Second Clinical School of North Sichuan Medical College,Nanchong 637000,China)

机构地区：[1]川北医学院第二临床医学院南充市中心医院心内科,南充637000

出　　处：《西北药学杂志》2023年第1期133-140,共8页Northwest Pharmaceutical Journal

基　　金：国家科技重大专项课题(编号:2012ZX09101101)。

摘　　要：目的比较高血压伴高尿酸血症患者应用左氨氯地平、氨氯地平治疗的临床疗效。方法将高血压伴高尿酸血症患者作为研究对象,左氨氯地平组339例、氨氯地平组221例。对比分析2组患者的临床疗效、各指标变化差异。结果治疗后,2组患者的血压均明显下降,左氨氯地平组患者的血压低于氨氯地平组(P<0.05),氨氯地平组的降压效果明显劣于左氨氯地平组(P<0.001);2组患者血尿酸水平均明显低于治疗前,左氨氯地平组患者的血尿酸水平明显低于氨氯地平组(P<0.05);左氨氯地平组患者血压控制达标率高于氨氯地平组,多因素回归模型分析左氨氯地平可提高血压控制达标率(OR=2.030,95%CI:1.136~3.630);左氨氯地平组主要心血管不良事件(major adverse cardiovascular events,MACE)发生情况与氨氯地平组比较差异无统计学意义(P>0.05),多因素回归模型分析左氨氯地平对MACE的发生无明显影响(OR=0.892,95%CI:0.461~1.727);左氨氯地平组不良反应的发生情况与氨氯地平组比较差异无统计学意义(P>0.05),多因素回归模型分析左氨氯地平对不良反应无明显影响(OR=0.500,95%CI:0.235~1.061)。结论与氨氯地平相比,左氨氯地平在高血压伴高尿酸血症患者临床治疗中降压效果更明显,能有效提高血压控制达标率,且不会增加临床主要不良心血管事件以及不良反应发生的风险。Objective To compare the clinical efficacy of levoamlodipine and amlodipine in the treatment of hypertensive patients with hyperuricemia.Methods The subjects were hypertensive patients with hyperuricemia,including 339 patients in the levoamlodipine group and 221 patients in the amlodipine group.The differences in clinical efficacy and indicators between the 2 groups were compared and analyzed.Results After treatment,the blood pressure in both groups decreased significantly,and the blood pressure in the levoamlodipine group was lower than that in the amlodipine group(P<0.05),and the antihypertensive effect of amlodipine group was significantly lower than that of levoamlodipine group(P<0.001);The serum uric acid level in both groups was significantly lower than before treatment,and the serum uric acid level in the levoamlodipine group was significantly lower than that in the amlodipine group(P<0.05);The blood pressure compliance rate of the levoamlodipine group was higher than that of the amlodipine group.Multivariate regression analysis showed that levoamlodipine could increase the blood pressure compliance rate(OR=2.030,95%CI:1.136-3.630);There was no significant difference in major adverse cardiovascular events(MACE)between the levoamlodipine group and the amlodipine group(P>0.05),and the multivariate regression model showed no significant effect of levamlodipine on MACE(OR=0.892,95%CI:0.461-1.727);There was no significant difference in adverse drug reaction(ADR)between the levoamlodipine group and the amlodipine group(P>0.05),and the multivariate regression model showed no significant effect of levoamlodipine on active response(OR=0.500,95%CI:0.235-1.061).Conclusion Compared with amlodipine,levoamlodipine has a more obvious antihypertensive effect in clinical treatment of patients with hypertension and hyperuricemia,and effectively improves the compliance rate of blood pressure control without increasing the risk of major clinical adverse cardiovascular events and adverse reactions.

关 键 词：左氨氯地平 氨氯地平 高血压 高尿酸血症 

分 类 号：R972[医药卫生—药品]